Development of novel microprecipitated bulk powder (MBP) technology for manufacturing stable amorphous formulations of poorly soluble drugs

A novel method was developed to manufacture amorphous formulations of poorly soluble compounds that cannot be processed with existing methods such as spray drying and melt extrusion. The manufacturing process and the characterization of the resulting amorphous dispersion are presented via examples o...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of pharmaceutics Vol. 438; no. 1-2; pp. 53 - 60
Main Authors Shah, Navnit, Sandhu, Harpreet, Phuapradit, Wantanee, Pinal, Rodolfo, Iyer, Raman, Albano, Antonio, Chatterji, Ashish, Anand, Shalini, Choi, Duk Soon, Tang, Kin, Tian, Hung, Chokshi, Hitesh, Singhal, Dharmendra, Malick, Waseem
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 15.11.2012
Subjects
Online AccessGet full text

Cover

Loading…
Abstract A novel method was developed to manufacture amorphous formulations of poorly soluble compounds that cannot be processed with existing methods such as spray drying and melt extrusion. The manufacturing process and the characterization of the resulting amorphous dispersion are presented via examples of two research compounds. The novel process is utilized N,N-dimethylacetamide (DMA) to dissolve the drug and the selected ionic polymer. This solution is then co-precipitated into aqueous medium. The solvent is extracted out by washing and the co-precipitated material is isolated by filtration followed by drying. The dried material is referred to as microprecipitated bulk powder (MBP). The amorphous form prepared using this method not only provides excellent in vitro and in vivo performance but also showed excellent stability. The stabilization of amorphous dispersion is attributed to the high Tg, ionic nature of the polymer that help to stabilize the amorphous form by possible ionic interactions, and/or due to the insolubility of polymer in water. In addition to being an alternate technology for amorphous formulation of difficult compounds, MBP technology provides advantages with respect to stability, density and downstream processing.
AbstractList A novel method was developed to manufacture amorphous formulations of poorly soluble compounds that cannot be processed with existing methods such as spray drying and melt extrusion. The manufacturing process and the characterization of the resulting amorphous dispersion are presented via examples of two research compounds. The novel process is utilized N,N-dimethylacetamide (DMA) to dissolve the drug and the selected ionic polymer. This solution is then co-precipitated into aqueous medium. The solvent is extracted out by washing and the co-precipitated material is isolated by filtration followed by drying. The dried material is referred to as microprecipitated bulk powder (MBP). The amorphous form prepared using this method not only provides excellent in vitro and in vivo performance but also showed excellent stability. The stabilization of amorphous dispersion is attributed to the high Tg, ionic nature of the polymer that help to stabilize the amorphous form by possible ionic interactions, and/or due to the insolubility of polymer in water. In addition to being an alternate technology for amorphous formulation of difficult compounds, MBP technology provides advantages with respect to stability, density and downstream processing.
A novel method was developed to manufacture amorphous formulations of poorly soluble compounds that cannot be processed with existing methods such as spray drying and melt extrusion. The manufacturing process and the characterization of the resulting amorphous dispersion are presented via examples of two research compounds. The novel process is utilized N,N-dimethylacetamide (DMA) to dissolve the drug and the selected ionic polymer. This solution is then co-precipitated into aqueous medium. The solvent is extracted out by washing and the co-precipitated material is isolated by filtration followed by drying. The dried material is referred to as microprecipitated bulk powder (MBP). The amorphous form prepared using this method not only provides excellent in vitro and in vivo performance but also showed excellent stability. The stabilization of amorphous dispersion is attributed to the high T(g), ionic nature of the polymer that help to stabilize the amorphous form by possible ionic interactions, and/or due to the insolubility of polymer in water. In addition to being an alternate technology for amorphous formulation of difficult compounds, MBP technology provides advantages with respect to stability, density and downstream processing.
Author Phuapradit, Wantanee
Shah, Navnit
Tang, Kin
Choi, Duk Soon
Albano, Antonio
Chatterji, Ashish
Malick, Waseem
Iyer, Raman
Pinal, Rodolfo
Anand, Shalini
Singhal, Dharmendra
Tian, Hung
Sandhu, Harpreet
Chokshi, Hitesh
Author_xml – sequence: 1
  givenname: Navnit
  surname: Shah
  fullname: Shah, Navnit
  organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA
– sequence: 2
  givenname: Harpreet
  surname: Sandhu
  fullname: Sandhu, Harpreet
  email: Harpreet_K.sandhu@roche.com
  organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA
– sequence: 3
  givenname: Wantanee
  surname: Phuapradit
  fullname: Phuapradit, Wantanee
  organization: Kashiv Pharma, Piscataway, NJ, USA
– sequence: 4
  givenname: Rodolfo
  surname: Pinal
  fullname: Pinal, Rodolfo
  organization: Purdue University, Lafayette, IN, USA
– sequence: 5
  givenname: Raman
  surname: Iyer
  fullname: Iyer, Raman
  organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA
– sequence: 6
  givenname: Antonio
  surname: Albano
  fullname: Albano, Antonio
  organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA
– sequence: 7
  givenname: Ashish
  surname: Chatterji
  fullname: Chatterji, Ashish
  organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA
– sequence: 8
  givenname: Shalini
  surname: Anand
  fullname: Anand, Shalini
  organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA
– sequence: 9
  givenname: Duk Soon
  surname: Choi
  fullname: Choi, Duk Soon
  organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA
– sequence: 10
  givenname: Kin
  surname: Tang
  fullname: Tang, Kin
  organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA
– sequence: 11
  givenname: Hung
  surname: Tian
  fullname: Tian, Hung
  organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA
– sequence: 12
  givenname: Hitesh
  surname: Chokshi
  fullname: Chokshi, Hitesh
  organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA
– sequence: 13
  givenname: Dharmendra
  surname: Singhal
  fullname: Singhal, Dharmendra
  organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA
– sequence: 14
  givenname: Waseem
  surname: Malick
  fullname: Malick, Waseem
  organization: Pharmaceutical & Analytical R & D, Hoffmann-La-Roche, Nutley, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/22974525$$D View this record in MEDLINE/PubMed
BookMark eNqFkctu1DAUhi1URKeFRwC8LIsEXxI7WSEoV6kIJOjacuyTGQ9JnNpO0TwDL42jGdjWC1uWvvOfo_NdoLPJT4DQc0pKSqh4vS_dft7pMJaMUFaSpiScPkIb2khe8EqKM7QhXDZFTSU_Rxcx7gkhglH-BJ0z1sqqZvUG_XkP9zD4eYQpYd_jyecvHp0Jfg5g3OySTmBxtwy_8Ox_Wwj46uu7769wArOb_OC3B9z7gEc9Lb02aQlu2uKYdDcA1qMP884vcUXGZdDJ-SmufWbvw3DA0Q_LCtqwbONT9LjXQ4Rnp_cS3X788PP6c3Hz7dOX67c3hakYS0XNuTAgrBBtI9tK8AryZUzf6r7SQoIFaXknwBJmjNYNyI4DFxVv287qll-iq2PuHPzdAjGp0UUDw6AnyLMqmsGW8KaiD6P5NKJikmS0PqJ5dTEG6NUc3KjDQVGiVmVqr07K1KpMkUZlZbnuxanF0o1g_1f9c5SBl0eg117pbXBR3f7ICTXJKTWTK_HmSEDe2r2DoKJxMBmwLjtMynr3wBB_ASqDuOw
CitedBy_id crossref_primary_10_1016_j_ijpharm_2017_10_051
crossref_primary_10_1021_jm401329s
crossref_primary_10_1080_17425247_2016_1198769
crossref_primary_10_1002_jps_24541
crossref_primary_10_1016_j_ijpharm_2022_122043
crossref_primary_10_1016_j_ijpharm_2020_119836
crossref_primary_10_1021_acs_oprd_1c00380
crossref_primary_10_1007_s11095_022_03308_9
crossref_primary_10_1111_jphp_12984
crossref_primary_10_3390_pharmaceutics13122017
crossref_primary_10_1016_j_ijpharm_2020_119560
crossref_primary_10_1016_S1773_2247_13_50057_8
crossref_primary_10_1080_03639045_2018_1562467
crossref_primary_10_1208_s12249_018_0988_1
crossref_primary_10_1016_j_ijpharm_2015_03_053
crossref_primary_10_1016_j_xphs_2023_02_012
crossref_primary_10_1016_j_ajps_2023_100834
crossref_primary_10_1016_j_xphs_2022_09_007
crossref_primary_10_1016_j_xphs_2023_02_011
crossref_primary_10_1208_s12249_015_0395_9
crossref_primary_10_1016_j_ijpharm_2017_04_007
crossref_primary_10_1208_s12249_018_1007_2
crossref_primary_10_1002_crat_202300296
crossref_primary_10_1208_s12249_015_0393_y
crossref_primary_10_2174_1381612826666200701134135
crossref_primary_10_1016_j_ejca_2022_06_031
crossref_primary_10_1016_j_ijpharm_2013_04_040
crossref_primary_10_1016_j_ijpharm_2015_08_016
crossref_primary_10_1016_j_ijpharm_2014_08_016
crossref_primary_10_1016_S1773_2247_14_50033_0
crossref_primary_10_3109_03639045_2015_1075031
crossref_primary_10_1016_j_ijpharm_2021_121216
crossref_primary_10_2139_ssrn_4065567
crossref_primary_10_3390_polym12081679
crossref_primary_10_3109_03639045_2015_1018274
crossref_primary_10_1007_s40005_022_00568_w
crossref_primary_10_1016_j_xphs_2023_02_005
crossref_primary_10_1016_j_xphs_2021_02_004
crossref_primary_10_1016_j_ejpb_2013_03_013
crossref_primary_10_1016_j_ejpb_2013_09_007
crossref_primary_10_3390_pharmaceutics13071034
crossref_primary_10_1016_j_ijpx_2024_100259
crossref_primary_10_1016_j_xphs_2017_07_001
crossref_primary_10_1021_acs_molpharmaceut_2c00456
crossref_primary_10_1208_s12249_017_0861_7
crossref_primary_10_1021_acs_molpharmaceut_0c00198
crossref_primary_10_1016_j_ejps_2017_06_019
crossref_primary_10_1016_j_xphs_2020_12_033
crossref_primary_10_1007_s13346_018_0494_8
crossref_primary_10_1016_j_ijpharm_2019_01_009
crossref_primary_10_1111_jphp_12805
crossref_primary_10_1208_s12249_018_1082_4
crossref_primary_10_1016_j_ijpharm_2013_05_061
crossref_primary_10_3390_ma16206616
crossref_primary_10_1021_acs_molpharmaceut_8b00125
Cites_doi 10.1016/S0378-5173(02)00173-4
10.1016/S0939-6411(00)00076-X
10.1021/mp8000793
10.1016/j.ijpharm.2011.08.007
10.1615/CritRevTherDrugCarrierSyst.v21.i3.10
10.1021/mp8001073
10.1200/JCO.2004.12.007
10.1021/mp9002283
10.1039/c001905d
10.1248/cpb.9.866
10.1002/jps.2600800820
10.1007/s11095-009-9970-7
10.1021/mp0700211
10.1016/S0378-5173(02)00331-9
10.1111/j.2042-7158.2003.tb02431.x
10.1016/j.ijpharm.2007.12.017
10.1081/DDC-120030422
ContentType Journal Article
Copyright 2012 Elsevier B.V.
Copyright © 2012 Elsevier B.V. All rights reserved.
Copyright_xml – notice: 2012 Elsevier B.V.
– notice: Copyright © 2012 Elsevier B.V. All rights reserved.
DBID FBQ
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
7QO
8FD
FR3
P64
DOI 10.1016/j.ijpharm.2012.08.031
DatabaseName AGRIS
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
Biotechnology Research Abstracts
Technology Research Database
Engineering Research Database
Biotechnology and BioEngineering Abstracts
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
Engineering Research Database
Biotechnology Research Abstracts
Technology Research Database
Biotechnology and BioEngineering Abstracts
DatabaseTitleList
MEDLINE - Academic
MEDLINE
Engineering Research Database

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: FBQ
  name: AGRIS
  url: http://www.fao.org/agris/Centre.asp?Menu_1ID=DB&Menu_2ID=DB1&Language=EN&Content=http://www.fao.org/agris/search?Language=EN
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1873-3476
EndPage 60
ExternalDocumentID 10_1016_j_ijpharm_2012_08_031
22974525
US201500125275
S0378517312008265
Genre Journal Article
GroupedDBID ---
--K
--M
.~1
0R~
1B1
1RT
1~.
1~5
4.4
457
4G.
5GY
5VS
7-5
71M
8P~
9JM
AABNK
AACTN
AAEDT
AAEDW
AAIAV
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AATCM
AAXUO
ABFNM
ABFRF
ABJNI
ABMAC
ABOCM
ABXDB
ABYKQ
ABZDS
ACDAQ
ACGFO
ACGFS
ACIUM
ACRLP
ADBBV
ADEZE
ADMUD
AEBSH
AEFWE
AEKER
AENEX
AFKWA
AFTJW
AFXIZ
AGHFR
AGUBO
AGYEJ
AHHHB
AIEXJ
AIKHN
AITUG
AJBFU
AJOXV
ALCLG
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
AXJTR
BKOJK
BLXMC
C45
CS3
DU5
EBS
EFJIC
EFLBG
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FIRID
FNPLU
FYGXN
G-Q
GBLVA
HZ~
IHE
J1W
KOM
M34
M41
MO0
N9A
O-L
O9-
OAUVE
OGGZJ
OVD
OZT
P-8
P-9
P2P
PC.
Q38
RIG
ROL
RPZ
SCC
SDF
SDG
SDP
SES
SPCBC
SSP
SSZ
T5K
TEORI
~02
~G-
.GJ
29J
3O-
53G
AAQXK
ABPIF
ABPTK
ASPBG
AVWKF
AZFZN
FBQ
FEDTE
FGOYB
G-2
HMT
HVGLF
R2-
SEW
SPT
WUQ
ZXP
AAXKI
AKRWK
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
AFJKZ
CITATION
7X8
7QO
8FD
FR3
P64
ID FETCH-LOGICAL-c422t-5336ce6d6698794634e463ccf9af4a67ede7d3b6ed02ccaa8e7b3e364399bda93
IEDL.DBID AIKHN
ISSN 0378-5173
IngestDate Fri Oct 25 03:20:53 EDT 2024
Sat Oct 05 05:47:08 EDT 2024
Thu Sep 26 16:59:30 EDT 2024
Sat Sep 28 08:05:44 EDT 2024
Wed Dec 27 18:58:14 EST 2023
Fri Feb 23 02:20:35 EST 2024
IsPeerReviewed true
IsScholarly true
Issue 1-2
Keywords EPK
SCP
HME
Amorphous
DMA
Solid dispersion
MBP
PK
Solid solution
MAP
Co-precipitation
PXRD
Language English
License Copyright © 2012 Elsevier B.V. All rights reserved.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c422t-5336ce6d6698794634e463ccf9af4a67ede7d3b6ed02ccaa8e7b3e364399bda93
Notes http://dx.doi.org/10.1016/j.ijpharm.2012.08.031
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
PMID 22974525
PQID 1111864270
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_1399903841
proquest_miscellaneous_1111864270
crossref_primary_10_1016_j_ijpharm_2012_08_031
pubmed_primary_22974525
fao_agris_US201500125275
elsevier_sciencedirect_doi_10_1016_j_ijpharm_2012_08_031
PublicationCentury 2000
PublicationDate 2012-11-15
PublicationDateYYYYMMDD 2012-11-15
PublicationDate_xml – month: 11
  year: 2012
  text: 2012-11-15
  day: 15
PublicationDecade 2010
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle International journal of pharmaceutics
PublicationTitleAlternate Int J Pharm
PublicationYear 2012
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References Kislalioglu, Khan, Blount, Goettsch, Bolton (bib0050) 1991; 80
Maniruzzaman, Rana, Boateng, Mitchell, Douroumis (bib0070) 2012
Rumondor, Ivanisevic, Bates, Alonzo, Taylor (bib0075) 2009; 26
Matteucci, Brettmann, Rogers, Elder, Williams, Johnson (bib0065) 2007; 4
Albano A. Phuapradit W. Sandhu H., Shah N., 2002. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability. US Patent 6486329.
Sekiguchi, Obi (bib0085) 1961; 29
Leuner, Dressman (bib0060) 2000; 50
Sertsou, Butler, Scott, Hempenstall, Rades (bib0090) 2002; 245
Habib (bib0025) 2001
Hughey, Keen, Brough, Saeger, McGinity (bib0035) 2011; 419
Dupont, Bienvenu, Aghajanian, Pezzuli, Sabbatini, Vongphrachanh, Chang, Perkell, Ng, Passe, Briemer, Zhi, DeMario, Spriggs, Soignet (bib0020) 2004; 22
Lakshman, Cao, Kowalski, Serajuddin (bib0055) 2008; 5
Sertsou, Butler, Hempenstall, Rades (bib0095) 2003; 55
Kestur, Taylor (bib0045) 2010; 12
Dong, Chatterji, Sandhu, Choi, Chokshi, Shah (bib0015) 2008; 355
Hu, Johnston, Williams (bib0030) 2004; 30
Rumondor, Taylor (bib0080) 2010; 7
Cilurzo, Minghetti, Casiraghi, Montanari (bib0010) 2002; 242
Friesen, Shankar, Crew, Smithey, Curatolo, Nightangle (bib0105) 2008; 5
Kaushal, Gupta, Bansal (bib0040) 2004; 21
Cilurzo (10.1016/j.ijpharm.2012.08.031_bib0010) 2002; 242
Kaushal (10.1016/j.ijpharm.2012.08.031_bib0040) 2004; 21
Rumondor (10.1016/j.ijpharm.2012.08.031_bib0075) 2009; 26
Dong (10.1016/j.ijpharm.2012.08.031_bib0015) 2008; 355
10.1016/j.ijpharm.2012.08.031_bib0100
Hu (10.1016/j.ijpharm.2012.08.031_bib0030) 2004; 30
Kislalioglu (10.1016/j.ijpharm.2012.08.031_bib0050) 1991; 80
Lakshman (10.1016/j.ijpharm.2012.08.031_bib0055) 2008; 5
Kestur (10.1016/j.ijpharm.2012.08.031_bib0045) 2010; 12
Hughey (10.1016/j.ijpharm.2012.08.031_bib0035) 2011; 419
Friesen (10.1016/j.ijpharm.2012.08.031_bib0105) 2008; 5
Sekiguchi (10.1016/j.ijpharm.2012.08.031_bib0085) 1961; 29
Sertsou (10.1016/j.ijpharm.2012.08.031_bib0095) 2003; 55
Maniruzzaman (10.1016/j.ijpharm.2012.08.031_bib0070) 2012
Rumondor (10.1016/j.ijpharm.2012.08.031_bib0080) 2010; 7
Dupont (10.1016/j.ijpharm.2012.08.031_bib0020) 2004; 22
Leuner (10.1016/j.ijpharm.2012.08.031_bib0060) 2000; 50
Habib (10.1016/j.ijpharm.2012.08.031_bib0025) 2001
Matteucci (10.1016/j.ijpharm.2012.08.031_bib0065) 2007; 4
Sertsou (10.1016/j.ijpharm.2012.08.031_bib0090) 2002; 245
References_xml – volume: 5
  start-page: 994
  year: 2008
  end-page: 1002
  ident: bib0055
  article-title: Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug
  publication-title: Mol. Pharm.
  contributor:
    fullname: Serajuddin
– volume: 26
  start-page: 2523
  year: 2009
  end-page: 2535
  ident: bib0075
  article-title: Evaluation of drug–polymer miscibility in amorphous solid dispersion systems
  publication-title: Pharm. Res.
  contributor:
    fullname: Taylor
– volume: 21
  start-page: 133
  year: 2004
  end-page: 193
  ident: bib0040
  article-title: Amorphous drug delivery systems: molecular aspects, design and performance
  publication-title: Crit. Rev. Ther. Drug Carrier Syst.
  contributor:
    fullname: Bansal
– volume: 355
  start-page: 141
  year: 2008
  end-page: 149
  ident: bib0015
  article-title: Evaluation of solid state properties of solid dispersions prepared by hot–melt extrusion and solvent co-precipitation
  publication-title: Int. J. Pharm.
  contributor:
    fullname: Shah
– volume: 242
  start-page: 313
  year: 2002
  end-page: 317
  ident: bib0010
  article-title: Characterization of nifedipine solid dispersions
  publication-title: Int. J. Pharm.
  contributor:
    fullname: Montanari
– volume: 29
  start-page: 866
  year: 1961
  end-page: 867
  ident: bib0085
  article-title: New solid state dispersions for increasing dissolution rates
  publication-title: Chem. Pharm. Bull.
  contributor:
    fullname: Obi
– volume: 245
  start-page: 99
  year: 2002
  end-page: 108
  ident: bib0090
  article-title: Factors affecting incorporation of drug into solid solution with HPMCP during solvent change co-precipitation
  publication-title: Int. J. Pharm.
  contributor:
    fullname: Rades
– year: 2001
  ident: bib0025
  article-title: Fundamentals of Solid Dispersions
  contributor:
    fullname: Habib
– volume: 12
  start-page: 2390
  year: 2010
  end-page: 2397
  ident: bib0045
  article-title: Role of polymer chemistry in influencing crystal growth rates from amorphous felodipine
  publication-title: Cryst. Eng. Comm.
  contributor:
    fullname: Taylor
– volume: 30
  start-page: 233
  year: 2004
  end-page: 245
  ident: bib0030
  article-title: Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs
  publication-title: Drug Dev. Ind. Pharm.
  contributor:
    fullname: Williams
– volume: 4
  start-page: 782
  year: 2007
  end-page: 793
  ident: bib0065
  article-title: Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media
  publication-title: Mol. Pharm.
  contributor:
    fullname: Johnson
– volume: 7
  start-page: 477
  year: 2010
  end-page: 490
  ident: bib0080
  article-title: Effect of polymer hygroscopicity on the phase behavior of amorphous solid dispersions in the presence of moisture
  publication-title: Mol. Pharm.
  contributor:
    fullname: Taylor
– volume: 55
  start-page: 35
  year: 2003
  end-page: 41
  ident: bib0095
  article-title: Physical stability and enthalpy relaxation of drug–hypromellose phthalate solvent change co-precipitates
  publication-title: J. Pharm. Pharmacol.
  contributor:
    fullname: Rades
– volume: 50
  start-page: 47
  year: 2000
  end-page: 60
  ident: bib0060
  article-title: Improving drug solubility for oral delivery using solid dispersions
  publication-title: Eur. J. Pharm. Biopharm.
  contributor:
    fullname: Dressman
– year: 2012
  ident: bib0070
  article-title: Dissolution enhancement of poorly water-soluble APIs processed by hot-melt extrusion using hydrophilic polymers
  publication-title: Drug Dev. Ind. Pharm.
  contributor:
    fullname: Douroumis
– volume: 419
  start-page: 222
  year: 2011
  end-page: 230
  ident: bib0035
  article-title: Thermal processing of a poorly water-soluble drug substance exhibiting a high melting point: the utility of KinetiSol
  publication-title: Int. J. Pharm.
  contributor:
    fullname: McGinity
– volume: 80
  start-page: 799
  year: 1991
  end-page: 804
  ident: bib0050
  article-title: Physical characterization and dissolution properties of ibuprofen: Eudragit coprecipitates
  publication-title: J. Pharm. Sci.
  contributor:
    fullname: Bolton
– volume: 22
  start-page: 3366
  year: 2004
  end-page: 3376
  ident: bib0020
  article-title: Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors
  publication-title: J. Clin. Oncol.
  contributor:
    fullname: Soignet
– volume: 5
  start-page: 1003
  year: 2008
  end-page: 1019
  ident: bib0105
  article-title: Hydroxypropyl methylcellulose Acetate Succinate-Based Spray Dried Dispersions: An Overview
  publication-title: Mol. Pharm.
  contributor:
    fullname: Nightangle
– volume: 242
  start-page: 313
  year: 2002
  ident: 10.1016/j.ijpharm.2012.08.031_bib0010
  article-title: Characterization of nifedipine solid dispersions
  publication-title: Int. J. Pharm.
  doi: 10.1016/S0378-5173(02)00173-4
  contributor:
    fullname: Cilurzo
– volume: 50
  start-page: 47
  year: 2000
  ident: 10.1016/j.ijpharm.2012.08.031_bib0060
  article-title: Improving drug solubility for oral delivery using solid dispersions
  publication-title: Eur. J. Pharm. Biopharm.
  doi: 10.1016/S0939-6411(00)00076-X
  contributor:
    fullname: Leuner
– volume: 5
  start-page: 1003
  issue: 6
  year: 2008
  ident: 10.1016/j.ijpharm.2012.08.031_bib0105
  article-title: Hydroxypropyl methylcellulose Acetate Succinate-Based Spray Dried Dispersions: An Overview
  publication-title: Mol. Pharm.
  doi: 10.1021/mp8000793
  contributor:
    fullname: Friesen
– ident: 10.1016/j.ijpharm.2012.08.031_bib0100
– volume: 419
  start-page: 222
  year: 2011
  ident: 10.1016/j.ijpharm.2012.08.031_bib0035
  article-title: Thermal processing of a poorly water-soluble drug substance exhibiting a high melting point: the utility of KinetiSol® dispersing
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2011.08.007
  contributor:
    fullname: Hughey
– volume: 21
  start-page: 133
  year: 2004
  ident: 10.1016/j.ijpharm.2012.08.031_bib0040
  article-title: Amorphous drug delivery systems: molecular aspects, design and performance
  publication-title: Crit. Rev. Ther. Drug Carrier Syst.
  doi: 10.1615/CritRevTherDrugCarrierSyst.v21.i3.10
  contributor:
    fullname: Kaushal
– year: 2001
  ident: 10.1016/j.ijpharm.2012.08.031_bib0025
  contributor:
    fullname: Habib
– volume: 5
  start-page: 994
  year: 2008
  ident: 10.1016/j.ijpharm.2012.08.031_bib0055
  article-title: Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug
  publication-title: Mol. Pharm.
  doi: 10.1021/mp8001073
  contributor:
    fullname: Lakshman
– volume: 22
  start-page: 3366
  year: 2004
  ident: 10.1016/j.ijpharm.2012.08.031_bib0020
  article-title: Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2004.12.007
  contributor:
    fullname: Dupont
– volume: 7
  start-page: 477
  year: 2010
  ident: 10.1016/j.ijpharm.2012.08.031_bib0080
  article-title: Effect of polymer hygroscopicity on the phase behavior of amorphous solid dispersions in the presence of moisture
  publication-title: Mol. Pharm.
  doi: 10.1021/mp9002283
  contributor:
    fullname: Rumondor
– year: 2012
  ident: 10.1016/j.ijpharm.2012.08.031_bib0070
  article-title: Dissolution enhancement of poorly water-soluble APIs processed by hot-melt extrusion using hydrophilic polymers
  publication-title: Drug Dev. Ind. Pharm.
  contributor:
    fullname: Maniruzzaman
– volume: 12
  start-page: 2390
  year: 2010
  ident: 10.1016/j.ijpharm.2012.08.031_bib0045
  article-title: Role of polymer chemistry in influencing crystal growth rates from amorphous felodipine
  publication-title: Cryst. Eng. Comm.
  doi: 10.1039/c001905d
  contributor:
    fullname: Kestur
– volume: 29
  start-page: 866
  year: 1961
  ident: 10.1016/j.ijpharm.2012.08.031_bib0085
  article-title: New solid state dispersions for increasing dissolution rates
  publication-title: Chem. Pharm. Bull.
  doi: 10.1248/cpb.9.866
  contributor:
    fullname: Sekiguchi
– volume: 80
  start-page: 799
  year: 1991
  ident: 10.1016/j.ijpharm.2012.08.031_bib0050
  article-title: Physical characterization and dissolution properties of ibuprofen: Eudragit coprecipitates
  publication-title: J. Pharm. Sci.
  doi: 10.1002/jps.2600800820
  contributor:
    fullname: Kislalioglu
– volume: 26
  start-page: 2523
  year: 2009
  ident: 10.1016/j.ijpharm.2012.08.031_bib0075
  article-title: Evaluation of drug–polymer miscibility in amorphous solid dispersion systems
  publication-title: Pharm. Res.
  doi: 10.1007/s11095-009-9970-7
  contributor:
    fullname: Rumondor
– volume: 4
  start-page: 782
  year: 2007
  ident: 10.1016/j.ijpharm.2012.08.031_bib0065
  article-title: Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media
  publication-title: Mol. Pharm.
  doi: 10.1021/mp0700211
  contributor:
    fullname: Matteucci
– volume: 245
  start-page: 99
  year: 2002
  ident: 10.1016/j.ijpharm.2012.08.031_bib0090
  article-title: Factors affecting incorporation of drug into solid solution with HPMCP during solvent change co-precipitation
  publication-title: Int. J. Pharm.
  doi: 10.1016/S0378-5173(02)00331-9
  contributor:
    fullname: Sertsou
– volume: 55
  start-page: 35
  year: 2003
  ident: 10.1016/j.ijpharm.2012.08.031_bib0095
  article-title: Physical stability and enthalpy relaxation of drug–hypromellose phthalate solvent change co-precipitates
  publication-title: J. Pharm. Pharmacol.
  doi: 10.1111/j.2042-7158.2003.tb02431.x
  contributor:
    fullname: Sertsou
– volume: 355
  start-page: 141
  year: 2008
  ident: 10.1016/j.ijpharm.2012.08.031_bib0015
  article-title: Evaluation of solid state properties of solid dispersions prepared by hot–melt extrusion and solvent co-precipitation
  publication-title: Int. J. Pharm.
  doi: 10.1016/j.ijpharm.2007.12.017
  contributor:
    fullname: Dong
– volume: 30
  start-page: 233
  year: 2004
  ident: 10.1016/j.ijpharm.2012.08.031_bib0030
  article-title: Nanoparticle engineering processes for enhancing the dissolution rates of poorly water soluble drugs
  publication-title: Drug Dev. Ind. Pharm.
  doi: 10.1081/DDC-120030422
  contributor:
    fullname: Hu
SSID ssj0006213
Score 2.3824046
Snippet A novel method was developed to manufacture amorphous formulations of poorly soluble compounds that cannot be processed with existing methods such as spray...
SourceID proquest
crossref
pubmed
fao
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 53
SubjectTerms Acetamides - chemistry
Amorphous
Animals
Antineoplastic Agents - blood
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacokinetics
Co-precipitation
coprecipitation
Dogs
Drug Compounding - methods
drugs
extrusion
filtration
manufacturing
MBP
melting
methodology
Pharmaceutical Preparations - chemistry
polymers
Polymers - chemistry
Powders - chemistry
Powders - pharmacokinetics
Rats
Solid dispersion
Solid solution
Solubility
solvents
spray drying
washing
Title Development of novel microprecipitated bulk powder (MBP) technology for manufacturing stable amorphous formulations of poorly soluble drugs
URI https://dx.doi.org/10.1016/j.ijpharm.2012.08.031
https://www.ncbi.nlm.nih.gov/pubmed/22974525
https://search.proquest.com/docview/1111864270
https://search.proquest.com/docview/1399903841
Volume 438
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZN-rKXsXuzS9FglA3qxJZk2Xrsykq2sRJoA30zkiWXpIltkpiRl_2B_emd40uyPXSDvRhkS1jSOTr6jnQuhLxLw5QZxWAh8Uh4ItCpF2dZ4ClplLZpBiiiNpC9lOOp-HIT3hyQ884XBs0qW9nfyPRaWrdvRu1sjsrZbHTl8zqxPA_wCp_JsEcOYTticZ8cnn3-Or7cCWTJ2izJoDBhg70jz2g-nM1LjBGNRl6sDubJg_u2qF6mi_uBaL0hXTwiD1skSc-azj4mBy5_Qk4mTSjq7Sm93ntWrU_pCZ3sg1Rvn5Kfv1kL0SKjeQFFukTzvBIDXmAyEQCj1FSLO1oW361b0fffPk4-0M3uMJ4C4KVLnVfoHVG7O1LAmmbhqF4WQL-iWmOVZZshbI3_KYtitdhS5HisaFfV7foZmV58uj4fe21iBi8VjG08gIgyddJKqWIMUM-Fg0eaZkpnQsvIWRdZbqSzPgMO0bGLDHccwY8yViv-nPTzIndHhLJIxQCqTKgFF1JYFYG2bnwnmY58G2QDMuxokZRN_I2kM0ybJy3xEiReguk0eTAgcUex5A9GSmCP-FfTI6Bwom9BvCbTK4aHQfA1ZFE4IG87siew_vBSRecOprHWoGJQ4iL_L3Vg3MrnsYBfvGh4ZjcYxkCjC1n48v_7_Yo8wBJ6SAbha9LfrCr3BqDSxhyT3vBHcNwuiF-RqhSC
link.rule.ids 315,783,787,4509,24128,27936,27937,45597,45691
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBa9PGwvo7s2u2owygZ1Y0uybD12ZSVd2xBoAn0Tki2XZIltkpiS37A_vXMcO9keusFeDLYkLOkcHX1HOhdCPiVhwqxisJB4JDwRmMSLsyzwlLTKpEkGKKI2kO3L3kh8vw1vd8hZ6wuDZpWN7F_L9FpaN1-6zWx2y_G4e-PzOrE8D_AKn8lwl-wDGlCwOvdPLy57_Y1AlqzJkgwKEzbYOvJ0JyfjSYkxotHIi9XBPHnw0Ba1m5niYSBab0jnB-RJgyTp6bqzT8mOy5-Ro8E6FPXqmA63nlWLY3pEB9sg1avn5Odv1kK0yGhewCudoXleiQEvMJkIgFFqq-kPWhb3qZvTz9dfB1_ocnMYTwHw0pnJK_SOqN0dKWBNO3XUzAqgX1EtsMqsyRC2wP-URTGfrihyPFZM59Xd4gUZnX8bnvW8JjGDlwjGlh5ARJk4mUqpYgxQz4WDR5JkymTCyMilLkq5lS71GXCIiV1kueMIfpRNjeIvyV5e5O6QUBapGECVDY3gQopURaCtW99JZiI_DbIOOWlpoct1_A3dGqZNdEM8jcTTmE6TBx0StxTTfzCShj3iX00PgcLa3IF41aMbhodBUBqyKOyQjy3ZNaw_vFQxuYNprDWoGJS4yP9LHRi38nks4Bev1jyzGQxjoNGFLHz9__3-QB71htdX-uqif_mGPMYS9JYMwrdkbzmv3DuATUv7vlkWvwA-2BZ2
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+of+novel+microprecipitated+bulk+powder+%28MBP%29+technology+for+manufacturing+stable+amorphous+formulations+of+poorly+soluble+drugs&rft.jtitle=International+journal+of+pharmaceutics&rft.au=Shah%2C+Navnit&rft.au=Sandhu%2C+Harpreet&rft.au=Phuapradit%2C+Wantanee&rft.au=Pinal%2C+Rodolfo&rft.date=2012-11-15&rft.pub=Elsevier+B.V&rft.issn=0378-5173&rft.eissn=1873-3476&rft.volume=438&rft.issue=1-2&rft.spage=53&rft.epage=60&rft_id=info:doi/10.1016%2Fj.ijpharm.2012.08.031&rft.externalDocID=S0378517312008265
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0378-5173&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0378-5173&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0378-5173&client=summon